newsfilter
← Latest News
Business Wire·

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with